InnoSer News: February 2024
Read more about our preclinical research, general drug?development services and updates in our monthly LinkedIn newsletter. Read below about some of our February highlights across our therapeutic areas.
How to obtain the most value out of your neurodegenerative disease research????
To date, large ongoing efforts are being made to provide well-characterised animal models which are suitable for investigating novel therapeutics. To ensure full confidence in the efficacy profile of novel therapeutic agents, efficacy testing often needs to be performed in a selection of multiple models. In general, the choice of neurodegenerative mouse model can further depend on:?
InnoSer’s expert neurology research team has characterised multiple neurodegenerative disease mouse models and can help advise which model is the most suitable for your research.?
View the full newsletter on our website, to read more about current available Alzheimer’s, Parkinson’s and ALS disease preclinical research models: https://www.innoserlaboratories.com/newsletter/neurodegenerative-disease-research-models/??
In vivo tumorigenicity testing to evaluate your therapeutics’ safety?
For all novel therapy types in the immuno-oncology field such as immunotherapies, small molecule, biologics, ATMPs, gene therapeutics etc., rigorous preclinical research is the key to success in clinical trials.??
In this month’s newsletter we delve into how InnoSer’s expertise in the oncology field helps you obtain relevant insights beyond examining the efficacy profile of your novel therapeutic candidates. Learn more about our in vivo tumorigenicity testing here: https://www.innoserlaboratories.com/newsletter/in-vivo-tumorigenicity-testing-to-evaluate-your-therapeutics-safety/??
PK/PD and Tolerability Testing in the ADPKD Mouse Model?
Pharmacokinetic (PK) and Pharmacodynamic (PD) profiling helps inform for e.g., the most optimal dosing route, dosing regimens (dosage and frequency of dosing), formulation type, determination of therapeutic index, metabolic stability and clearance by precisely determining the identity and concentration of your test compounds in the blood or specific organs. In this newsletter, we discuss the importance of performing PK and tolerability/MTD studies in the ADPKD mouse model before commencing efficacy studies: https://www.innoserlaboratories.com/newsletter/pk-pd-and-tolerability-testing-in-the-adpkd-mouse-model/???
Latest cardiovascular and metabolic research news?
InnoSer offers a selection of gold standard cardio-metabolic disease models in rodents, supporting custom studies to optimize the preclinical development of your drug candidates.??
At InnoSer, we can provide you with a range of preclinical metabolic disease models relevant for GLP-1 receptor agonists, such as our diabetic cardiomyopathy rat model with progressive development of diabetes and cardiovascular complications and high fat or western diet mouse models to study metabolic dysfunction-Associated Fatty Liver Disease (MAFLD).??
Additionally, we also offer a multitude of key readouts to evaluate the effects of GLP-1 receptor agonists.?
Other readouts such as assessment of skeletal muscle function (Rotarod, grip strength test, treadmill, wire hanging and assessment of spontaneous motor function) can be performed to follow-up the effects of GLP-1 agonists on other organ systems. We have also recently shown that a selection of cognitive tests constitutes a valuable tool to investigate the effect of compounds in the setting of chronic metabolic disorders and cognitive performance.??
To learn more about how your research can benefit from our capabilities view the full newsletter on our webpage here:??https://www.innoserlaboratories.com/newsletter/latest-cardiovascular-and-metabolic-research-news/
Meet Us – Event Exhibitions
Our business development manager, Charlotte Wuyts together with our neurology study directors Thomas Vogels and Jolien Beeken are excited to be attending the AD/PD 2024! Meet us at booth #22!??
Our neurology study director Jolien Beeken will present poster (#262) titled Preclinical neuronal models to screen the effectiveness of drugs directed to slow down Alzheimer’s and Parkinson’s disease progression.??
Recent Blog Posts